Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC‐1 study of patients with relapsed/refractory multiple myelomaThomas G Martin, Cesar Rodriguez, Rachel Kobos et al.|Cancer|2023Cited by 66
Translational Approach of Using Ex Vivo Cytotoxicity and Early Clinical Data to Predict Teclistamab Efficacious Therapeutic Range in Multiple Myeloma PatientsSuzette Girgis, Amarnath Sharma, Shun Xin Wang Lin et al.|Blood|2020Cited by 2